stockrowGSK PLC Sponsored ADR
GSK Healthcare Drug Manufacturers General
GSK PLC Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $43.1 billion, up 7.44% from fiscal 2024.
- Revenue
- +3.75%
- EPS
- −14.7%
- Free cash flow
- +62.4%
- Total debt
- +33.2%
Quarter to September 2026, against a year earlier
Follow GSK
Alert me
GSK PLC Sponsored ADR (GSK) Net margin
GSK PLC Sponsored ADR's net margin over the twelve months to 30 September 2026 was 13.0%, down 4.5 percentage points from fiscal 2025 (17.5%). Over the past ten years it has ranged from 3.27% (fiscal 2016) to 51.0% (fiscal 2022); the current reading is higher than 82% of that period. That is above the Drug Manufacturers General industry median of 7.31% and above the Healthcare sector median of 0.00%.
Net margin, annual
Embed this chart
Annual newest first
| Period | Net margin | Change (points) |
|---|---|---|
| FY2025 | 17.5% | 9.29 |
| FY2024 | 8.21% | (8.04) |
| FY2023 | 16.3% | (34.75) |
| FY2022 | 51.0% | 38.15 |
| FY2021 | 12.9% | (4.01) |
| FY2020 | 16.9% | 3.10 |
| FY2019 | 13.8% | 2.01 |
| FY2018 | 11.8% | 6.67 |
| FY2017 | 5.08% | 1.81 |
| FY2016 | 3.27% | (31.93) |
Quarterly newest first
| Period | Net margin | Change (points) |
|---|---|---|
| Sep 2026 | 17.4% | 12.19 |
| Jun 2026 | 5.17% | (17.60) |
| Mar 2026 | 22.8% | 15.32 |
| Dec 2025 | 7.45% | (16.10) |
| 43 more quarters | Free account |
Against its own ten years
Net margin against peers
| Company | Net margin |
|---|---|
| NVO Novo Nordisk A/S compare | 35.5% |
| AMGN Amgen Inc. compare | 24.1% |
| BMY Bristol Myers Squibb Company compare | 18.5% |
| AZN AstraZeneca PLC compare | 17.7% |
| GSK GSK PLC Sponsored ADR | 13.0% |
| SNY Sanofi compare | 8.27% |
| PFE Pfizer Inc. compare | 6.34% |
| BIIB Biogen Inc. compare | 3.37% |
| GILD Gilead Sciences, Inc. compare | −12.5% |
| Drug Manufacturers General industry median | 7.31% |
| Healthcare sector median | 0.00% |
| Market median | 1.06% |
What Net margin is
Net Profit Margin tells an investor how much of each unit of revenue ends up as profit for shareholders after all costs, interest and taxes.
Net Income Allotted to Shareholders ÷ Revenue
More on GSK
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement